Physician profile
Raphael Kiel
NPI 1063482834
$1,310.70
in general payments reported to CMS, 2019-2025
20 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2024: $137 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $414.97 | 2019-2025 | Cabenuva, Dovato |
| Insmed, INC. | $151.03 | 2019-2025 | Arikayce |
| Gilead Sciences, INC. | $137.57 | 2019 | |
| Janssen Biotech, INC. | $103.28 | 2019-2025 | Rybrevant |
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $82.68 | 2019 | |
| Allergan, INC. | $78.35 | 2019 | |
| Abbvie INC. | $44.44 | 2019-2024 | |
| Melinta Therapeutics, LLC | $27.08 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.20 | 2019 | |
| Aimmune Therapeutics, INC. | $20.81 | 2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.15 | 2025 | |
| Genentech USA, INC. | $15.34 | 2025 | Itovebi |
| Array Biopharma INC | $15.26 | 2019 | |
| Dynavax Technologies Corporation | $15.03 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.89 | 2019 | |
| Theratechnologies INC. | $13.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.79 | 2019 | |
| Tersera Therapeutics LLC | $12.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Kiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.